CDC: US should resume use of Johnson & Johnson COVID-19 vaccine

By Alyssa Wilson Published: April 23, 2021

CDC: US should resume use of Johnson & Johnson COVID-19 vaccine

Boxes of Janssen vaccines sit at a warehouse of Hungaropharma, a Hungarian pharmaceutical wholesale company, in Budapest, Hungary, after the arrival of the first batch of the Johnson & Johnson, US, made one-dose vaccine against the new coronavirus in the country Tuesday, April 13, 2021. The first shopment contains 28 thousand doses of Janssen. (Szilard Koszticsak/MTI via AP)

The Centers for Disease Control and Prevention has recommended that the U.S. resume the use of the Johnson & Johnson COVID-19 vaccine.

According to CNBC, the CDC advisory panel said the benefits outweigh the risk.

The pause was announced on April 13 after the vaccine was linked to a rare blood clotting disorder known as cerebral venous sinus thrombosis.

A total of 13 reported cases were found in women between the ages of 18-49 and two in women 50 and older, NPR reported.

Three of the 15 women died and no cases were found in men.

Members of the advisory committee proposed that the Food and Drug Administration add a warning label on the vaccine for women under the age of 50.

Although extremely rare, the news of the pause raised concerns for the vaccine hesitancy that already exists, especially in Black and brown communities.

Doctors are urging people to still get vaccinated against COVID-19.